Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P52742 (pT3)
 1,034 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Surgery plus adjuvant chemotherapy using MVP-CAB (Day 1; methotrexate 20 mg/m2, vincristine 0.6 mg/m2, cyclophosphamide 500 mg/m2, adriamycin 20 mg/m2, and bleomycin 30 mg, Day 2; cisplatinum 50 mg/m2) was conducted in 12 patients with epithelial tumors of the upper urinary tract who had unfavorable prognostic factors (progressive disease which was pT2 or more, or transitional cell carcinoma of grade 2 and 3). The MVP-CAB regimen was as follows: A total of 3 cycles were given either before or after surgery. MVP-CAB was given at 3- to 4-week intervals before surgery, or after surgery if the patient had macroscopic residual lesions. For the patients with micrometastases detected after radical surgery, MVP-CAB was given every 1 to 2 months. The median survival period of the 10 patients who underwent radical surgery was 17 months (5-59 months). The three-year survival rate of these 10 patients (Kaplan-Meier method) was 100% in grade 2 (5 patients), 100% in progressive cancer greater than pT3 (6), and 80% in grade 3 (5). In two patients, residual macroscopic lesions after surgery were confirmed. One of them initially responded to MVP-CAB but died of cancer 21 months later, while the other one did not respond and died of cancer 8 months later. Two renal pelvis cancer patients for whom radical surgery was considered impossible due to distant metastases showed remarkable tumor reduction after MVP-CAB administration (one showed CR for liver metastases and the other showed PR for lymph node metastases).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Adjuvant chemotherapy with MVP-CAB (methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin and bleomycin) for epithelial tumors of the upper urinary tract]. 127 58

The patient's age, tumour size, histological type and degree of differentiation as well as involvement of axillary lymph nodes are decisive for prognosis and therapy of breast cancer. Moreover these parameters reflect the achievement of early diagnosis and the surgical standard of treatment of breast carcinomas. Therefore we retrospectively reviewed 1510 cases diagnosed from 1984-1987. Non-invasive carcinomas were diagnosed in 4%. 75% of them were classified as intraductal carcinoma and 25% as lobular carcinoma in situ. 96% of the tumours were invasive at time of diagnosis. Invasive ductal carcinoma (NOS-type) was found in 70.2%, invasive lobular carcinoma in 12.3%. 3.2% of the tumours showed both ductal and lobular differentiation and 2.3% corresponded to invasive ductal carcinoma with a predominantly intraductal component. Medullary and mucinous carcinomas were detected in 2.1% and 2% of cases, respectively. Papillary carcinomas were observed in 0.9%, the frequency of other histological types was less than 1%. 44% of the tumours corresponded to UICC-category pT1, 38% to pT2, 6% to pT3 and 8% to pT4. A meaningful correlation of tumour size and axillary lymph node involvement was possible in only 906 cases, in which 10 or more lymph nodes were verified histologically. Lymph node metastases were detected in 23% of tumour category pT1 and in 47% of category pT2. PT3- and pT4-tumours metastasized to axillary lymph nodes in 77 and 86% of cases, respectively.
 ...
PMID:[Breast cancer in the catchment area of the Graz Institute of Pathology. Evaluation of morphologic parameters based on 1,510 cases]. 133 34

Sixty-six patients with renal pelvic and ureteral tumors were treated in our hospital between June 1974 and June 1991. These cases consisted of 27 renal pelvic tumors, 31 ureteral tumors and 8 renal pelvic and ureteral tumors. Their ages ranged from 43 to 86 years old (average: 65). There were 46 males and 20 females. The surgical method involved total nephroureterectomy with a cuff for 44 patients, nephroureterectomy for 3, nephrectomy for 9, total nephroureterectomy with total cystectomy for 5 and partial ureterectomy for 2. Histologically, there were 60 transitional cell carcinomas (TCC), 2 squamous cell carcinomas (SCC) and 4 TCC with SCC. As for the pathological stage, 13 were pTa, 16 pT1, 12 pT2, 11 pT3, 13 pT4 and 1 pTX. Subsequent bladder tumors were found in 13 patients (19.7%). The overall survival rate at 1, 3 and 5 years were 80%, 68% and 52%, respectively according to the Kaplan-Meier's method. In this series, the pathological staging was the most important prognostic factor.
 ...
PMID:[A clinical investigation on renal pelvic and ureteral tumors]. 141 51

Mortality rate of ovarian cancer is increasing in Japan and the management of advanced cases is an important issue in order to improve long term survival. Radical surgery including systematic lymphadenectomy (LNX) from paraaortic nodes through pelvic nodes was, therefore, performed in our department with regular surgery (TAH, BSO, omentectomy) and lymph node metastasis (LNM) was analyses. LNM rate of patients whose LNX done in the primary surgery according to pTNM classification was as follows: pT1: 9.7%, pT2: 1.1%, pT3: 66.7% and that of those LNX done at SLO was as follows: pT1: 8.3%, pT2: 0%, pT3: 69.2%. Since radical surgery improved prognosis of advanced ovarian cancer significantly radical surgery including LNX are strongly recommended as a treatment of advanced ovarian cancer.
 ...
PMID:[Radical surgery for ovarian cancer]. 141 6

58 patients with advanced bladder cancer were treated with MVEC chemotherapy (methotrexate, vinblastine, epirubicin and cisplatinum). 22 patients suffered from locally advanced disease (pT3-4 M0 N0), in 20 patients regional lymph node metastases were found (pT3-4 N1-3 M0). In 16 patients distant metastases were noted (pT1-4 N0-1 M1). In 89% transitional cell and in 11% squamous cell cancer or anaplastic carcinoma was seen. Complete response was noted in 45%, partial response in 23% and no response in 32%. Tissue polypeptide antigen (TPA) was registered before each course of chemotherapy and 3 months after the last application. The sensitivity for (pT3-4 N0 M0) tumors was 90.9%, for (pT3-4 N1-3 M0) 100% and for tumors with distant metastases 100% also, overall 96.6%. No statistically significant different values between each tumor group were found. In 85.7% a concordant reaction of TPA values and clinical status was notable. In conclusion, TPA has been proven as a valuable and a reliable marker for monitoring therapeutic efficacy of chemotherapy for advanced bladder cancer.
 ...
PMID:Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy. 142 31

We report about a patient who was treated with a percutaneous suprapubic cystostomy in order to relieve repeated urinary retention. Two hours later a bladder tumor was found and the suprapubic catheter was removed. After transurethral resection of the bladder tumor the histological specimen showed a pT3 G3 squamous cell carcinoma. Because of the age and reduced performance status of the patient a radical cystectomy was contraindicated. In a second approach we performed again a transurethral resection of the bladder tumor simultaneously with a resection of the prostate. Eight weeks later the patient was admitted to our hospital because of reduced performance status and gross haematuria. We found a widespread bladder tumor with an implantation metastasis in the abdominal wall at the site where the suprapubic catheter was placed and multiple lung metastases. The patient died within one week after admission. The literature is reviewed and therapeutic strategies are discussed.
 ...
PMID:Implantation metastasis after a suprapubic catheter in a case of bladder cancer. 142 51

A retrospective study of DNA content in 38 medium-rectal adenocarcinomas (a rectal part between 8 and 12 cm. from anus) was performed using flow cytometry in order to find probable correlations among ploidy, grading, staging and survival in patients who had undergone a surgical operation from January 1975 to December 1989. At the beginning of the work, 21 patients were alive and 17 were dead. Histologically 15 carcinomas (39.4%) were G1, 22 (57.8%) were G2 and only 1 (2.6%) was G3. Moreover 1 case (2.6%) was pT1, 7 (18.4%) were pT2 and 30 (78.9%) were pT3. 11 adenocarcinomas (29%) were euploid and 27 (71%) were aneuploid. These percentages agree with literature data. 11 of dead patients (64.7%) had aneuploid neoplasias and 6 (35.3%) diploid; 16 of alive patients (72.2%) had aneuploid carcinomas and 5 (23.8%) diploid. The difference of survival between aneuploid and diploid carcinomas isn't statistically significative (X2 = 0.168 ns). No correlation was found among aneuploidy, grading and staging, probably on account of small number of analyzed cases, owing to particular and little rectal part included in the study. Likely, having a larger case number we'll be able to obtain more incisive informations from this type of analysis in the next future.
 ...
PMID:[Prognostic value of cellular ploidy in adenocarcinoma of the middle rectum]. 143 5

Carbohydrate Antigen 19-9 (CA 19-9) histological expression in transitional cell bladder carcinoma (TCBC) was studied by means of immunohistochemistry and its findings compared with those of Tissue Polypeptidic Antigen (TPA) and Carcino Embryonic Antigen (CEA). Twenty-one TCBC of various grade and stage were analyzed by using Avidin-Biotin complex method for CA 19-9 and TPA Peroxidase-Antiperoxidase method for CEA. Grade 3 and pT1, pT2/pT3 carcinomas showed a constant staining for CA 19-9 antigen, grade 2 showed a 50% positive immunoreaction while all grade 1 cases were negative. TPA showed an inverse correlation with well differentiated carcinomas which were better and more extensively stained than anaplastic ones. CEA expression was not correlated either with grade or stage. CA 19-9 could be considered as a dedifferentiation marker in TCBC.
 ...
PMID:[Immunohistochemical determination of antigen 19-9 (CA 19-9) in transitional carcinoma of the bladder]. 149 66

A retrospective analysis of 59 patients with renal pelvic and ureter cancer (56 transitional cell carcinomas, 2 squamous cell carcinomas, and 1 adenocarcinoma), which were treated surgically, was performed in relation to postoperative recurrence, particularly distant metastasis. Of the 59 cases, postoperative recurrences developed as distant metastasis in 9 cases (15.3%), as bladder cancer in 19 cases (32.2%) and as contralateral renal pelvic and ureter cancer (bilateral metachronous cancer) in 3 cases (5.1%). Three of the 9 cases with the development of distant metastasis were squamous cell carcinoma or adenocarcinoma, and the others transitional cell carcinoma. All the metastases occurred within 2 years. In cases with transitional cell carcinoma, nonpapillary tumor, grade 3, high stage (pT3 and pT4), positive vascular invasion and IFN beta or gamma had a significant influence on the rate of distant metastasis. On the other hand, location, diversity and previous or coexistent bladder cancer did not seem to be related to the frequency of the development of distant metastasis. Thus, tumor aggressiveness was the only predictive valuable of the development of distant metastasis after surgery for renal pelvic and ureter cancer.
 ...
PMID:[Recurrence following surgery for primary renal pelvic and ureter cancer--clinicopathologic analysis of distant metastasis]. 149 3

During the last decades considerable progress was made in medical and biomedical techniques, enabling early diagnosis and a better understanding of how tumors develop. At the same time, treatment by surgery has changed, becoming less and less mutilating. In order to analyze loco-regional relapses and factors of prognosis, we studied 420 patients representing 415 cases of breast cancer, all of whom received breast-preservation therapy. The case histories were followed from 1 to 17 1/2 years, with an average observation period of 4 years. The majority of patients underwent enlarged tumorectomy, generally accompanied by axillary dissection and by radiotherapy. Based on an overall study of our patients, actuarial survival was 87% after 5 years and 65% after 10 years. Not taking into consideration patients with tumors at stages pT3 and pT4 recovery was 90% after 5 and 67% after 10 years. We have attempted to demonstrate that this survival rate, as well as the occurrence of a relapse, vary according to different parameters, such as size and invasion of the axillary glands.
 ...
PMID:[Non-mutilating treatment of breast cancer: survival and recurrence]. 152 38


1 2 3 4 5 6 7 8 9 10 Next >>